摘要:
A process for preparing 3aα-H-4α-[3'-propionic acid]-5a-hydroxy-7aβ-methyl-hexahydro-1-indanone-δ-)actone,having the formula
for the chemical synthesis of a pharmaceutical steroid, which includes cultivating, in the presence of cholesterol, sitosterol, stigmasterol, or a mixture of sitosterol and sitostanol, a mutant of the parent species R. australis of the genus Rhodococcus.
摘要:
A method of cutting a blank from which a container can be erected is disclosed, the blank being cut from a rectangular sheet of cardboard, corrugated board etc. The shape of the blank is such that corner portions of the sheet are cut away as waste. These corner portions are trimmed to rectangular shape, simultaneously with the cutting of the blank, and one or more slots are cut in them. These trimmed portions are used in a stack of containers to interlink upstanding pegs of adjacent containers, the pegs being passed through said slots.
摘要:
A method for the shrinkresist treatment of wool including the steps of chlorinating the wool with an acidified hypochlorite; dechlorinating the product; acidifying the product; and applying an acid colloid solution of suitable methylolmelamine resin to the product. The chlorination is preferably carried out in a suction drum in such a manner that the level of active chlorine on the wool is in excess of 2% (m/m).
摘要:
The invention provides a process for producing a purified plasminogen activator substance based on the TPA/pro-TPA couple. Pro-TPA yielding cell cultures are cultivated in a suitable culture medium in the absence of enzymes which catalyse the conversion of pro-TPA into TPA or where such enzymes are present in the presence of a suitable inhibitor adapted to inhibit such enzymes. Accord- : ingly the couple is represented in the harvesting liquid by at least 50 to 100% of pro-TPA and can in fact be virtually 100% pro-TPA, any balance being TPA. The harvesting fluid is treated with an affinity reagent comprising an immobilised Kunitz type inhibitor of the type occurring in seeds of Erythrina latissima and other Erythrina species (DE-3) to selectively adsorb the pro-TPA and any TPA in the harvesting fluid, followed by desorption of pro-TPA and optionally TPA. The pro-TPA so recoverable has 1/10 the plasminogen activating properties of TPA. It is convertable into active TPA enzymatically, e.g. by plasmin or by enzymes present in fibrin clots. The pro-TPA has a higher affinity for fibrin and better selectivity than TPA. It is used for the management and prophylaxis of thrombosis and embolism in dosages of pro-TPA/TPA couple which result in less than 50%, e.g. less than 20% of the plasminogen activating activity resulting from up to 15 mg/24 hrs pure TPA.
摘要:
The use of a rifamycin antibiotic, particularly rifampicin, in the treatment of ectoparasite borne diseases in animals, particularly heartwater. The rifamycin antibiotic may be administered intravenously, intramuscularly, orally or topically.
摘要:
The invention provides a process for producing a purified plasminogen activator substance based on the TPA/pro-TPA couple. Pro-TPA yielding cell cultures are cultivated in a suitable culture medium in the absence of enzymes which catalyse the conversion of pro-TPA into TPA or where such enzymes are present in the presence of a suitable inhibitor adapted to inhibit such enzymes. Accord- : ingly the couple is represented in the harvesting liquid by at least 50 to 100% of pro-TPA and can in fact be virtually 100% pro-TPA, any balance being TPA. The harvesting fluid is treated with an affinity reagent comprising an immobilised Kunitz type inhibitor of the type occurring in seeds of Erythrina latissima and other Erythrina species (DE-3) to selectively adsorb the pro-TPA and any TPA in the harvesting fluid, followed by desorption of pro-TPA and optionally TPA. The pro-TPA so recoverable has 1/10 the plasminogen activating properties of TPA. It is convertable into active TPA enzymatically, e.g. by plasmin or by enzymes present in fibrin clots. The pro-TPA has a higher affinity for fibrin and better selectivity than TPA. It is used for the management and prophylaxis of thrombosis and embolism in dosages of pro-TPA/TPA couple which result in less than 50%, e.g. less than 20% of the plasminogen activating activity resulting from up to 15 mg/24 hrs pure TPA.
摘要:
A composite floor structure comprising a floor slab (A1) of concrete or other compression resistant material (11) and at least one reinforced beam (B1) under the floor slab (A1). The beam (B1) comprises permanent shuttering including an open-mouthed, upwardly facing channel formation (1a) of steel or other tension resistant material; and a plurality of transverse members (5a) spaced apart along the length of the channel formation (1a) and extending transversely to the channel formation (1a) across substantially the entire width of the mouth of the channel formation (1a). Each transverse member (5a) is fast with the channel formation (1a) in the region of its mouth in zones (7a) on opposite sides of the mouth and at least part of at least certain of the transverse members (5a) extends upwardly from the region of the mouth of the channel formation (1a) into the overlying floor slab (A1). Concrete or other compression resistant material (11) is located in the channel formation (1a) and is formed integrally with the compression resistant material (11) of the floor slab (A1).